| Literature DB >> 18559497 |
Sylvie Galiègue-Zouitina1, Laure Delestré, Caroline Dupont, Xavier Troussard, Carl Simon Shelley.
Abstract
The cause of hairy cell leukemia (HCL) is unknown. Current treatments seem effective only for a limited period of time. In addition, a significant proportion of patients remain refractive to all treatment options. These considerations indicate the need to develop alternative therapeutic strategies for HCL. Here, we report that HCL is characterized by underexpression of RhoH. In vitro reconstitution of RhoH expression inhibits the aberrant adhesion and transendothelial migration that drives disease pathogenesis. In an in vivo model of HCL, RhoH reconstitution limits malignant progression and protects against mortality. These findings provide the proof of principle that RhoH reconstitution represents a potential new approach to the treatment of HCL.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18559497 DOI: 10.1158/0008-5472.CAN-07-5661
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701